Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on‐demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|3|320-329

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.3, 2015-05, pp. : 320-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on‐demand with bypass treatment

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 310-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 374-379

John Wiley & Sons Inc

Access to resources Recommend Favorite

Evidence for the Use of Activated Prothrombin Complex Concentrates (aPCCs) in the Treatment of Patients with Haemophilia and Inhibitors

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 32, Iss. 1, 2002-05 ,pp. : 9-12

Karger

Access to resources Recommend Favorite

COST-UTILITY ANALYSIS OF PRIMARY PROPHYLAXIS, COMPARED WITH ON-DEMAND TREATMENT, FOR PATIENTS WITH SEVERE HEMOPHILIA TYPE A IN COLOMBIA

By  

International Journal of Technology Assessment in Health Care, Vol. 32, Iss. 5, 2016-12 ,pp. : 337-347

Cambridge University Press

Access to resources Recommend Favorite

Activated Recombinant Human Coagulation Factor VII Therapy for Intracranial Hemorrhage in Patients with Hemophilia A or B with Inhibitors

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 2, 1999-03 ,pp. : 93-98

Karger

Access to resources Recommend Favorite